Anti-Human TFPI Reference Antibody (MG1113A)

Description: Anti-Human TFPI (MG1113A) (BS11909) is a research-grade recombinant antibody targeting Extrinsic pathway inhibitor. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Extrinsicpathwayinhibitor,Lipoprotein-associatedcoagulationinhibitor,TFPI,EPI,LACI,TFPI1,Tissuefactorpathwayinhibitor
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: MG1113A
Background: Tissue factor pathway inhibitor (TFPI) is a ~35 kDa protein. Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action and also the ability to associate with lipoproteins in plasma.
Note: For research use only. Not suitable for clinical or therapeutic use.